All articles
What is HRT for Menopause? Benefits & Risks
Reading time:
8 min
Menopause
Get expert guidance and a personalized care plan designed around you.
Benefits of HRT
Eliminates Hot Flashes and Night Sweats
HRT remains unmatched for treating vasomotor symptoms. Studies consistently show it eliminates or substantially reduces hot flashes and night sweats in most women, leading to better sleep and daily functioning.
Supports Brain Function and Mood
Research highlights that neurological symptoms like sleep disturbance, brain fog, and mood changes significantly impact quality of life, work productivity, and physical health during the menopausal transition. The relationship between estrogen and cognitive function is complex but crucial for many women experiencing mental fatigue, difficulty concentrating, or memory lapses.
Protects Your Heart
Perhaps the most compelling reason to consider HRT is its cardiovascular benefit, but only when initiated at the right time. According to research, HRT effects depend on timing of initiation, age, underlying tissue health, and treatment duration.
Starting early provides substantial protection against heart disease and reduces overall mortality. Starting late (more than 10 years post-menopause) offers no such benefits and may increase certain risks.
The Long-Term Survival Benefit
Research tracking over 1,000 women for nearly two decades provides clear evidence of HRT’s mortality benefit. The graph below shows cumulative survival probability over 18 years, comparing women who used HRT versus those who didn’t:
Figure adapted from Hodis HN, Mack WJ. Cancer Journal. 2022;28(3):208-223. This survival curve from the Danish Osteoporosis Study shows a statistically significant reduction of cardiovascular disease by 52% after 10 years of randomized hormone replacement therapy relative to no HRT, and reduction by 39% after 16 years of total follow-up.
What this graph shows: The blue line represents women using HRT, while the red dashed line represents women not using HRT. Higher lines mean better survival rates. The separation between the lines demonstrates that women using HRT had consistently better survival throughout the study period. The vertical dashed line at year 10 marks an important milestone, and the p-values (0.015 and 0.020) indicate these differences are statistically significant, not due to chance.
Preserves Bone Strength
Estrogen deficiency at menopause accelerates bone loss, increasing fracture risk. HRT effectively prevents this bone loss and reduces fractures, particularly in the spine and hip. These are injuries that can dramatically impact quality of life in older age.
May Improve Blood Sugar Control
Evidence suggests HRT can affect glucose control in women with diabetes and may influence diabetes risk in those without the condition. However, experts emphasize that HRT shouldn’t be used solely for diabetes prevention. For women with existing diabetes, treatment decisions should be individualized based on age, metabolic status, and cardiovascular risk factors.
Treats Vaginal and Sexual Problems
Vaginal dryness, painful intercourse, and urinary symptoms seriously affect many postmenopausal women’s sexual health and quality of life. Low-dose vaginal estrogen is the first-line treatment for these urogenital symptoms, with excellent effectiveness and minimal absorption into the bloodstream. Estriol, a weaker estrogen form, has gained recognition for safely and effectively treating genitourinary symptoms.
Risks of HRT
While people often exaggerate HRT risks, understanding actual risks helps you make informed decisions. All treatment options carry specific benefits and risks that vary by individual situation.
Breast Cancer Risk
This remains the primary concern for most women considering HRT, though the relationship is nuanced:
Estrogen-only therapy (for women post-hysterectomy) appears to carry lower breast cancer risk than combined therapy
Combined therapy risk varies with your baseline risk and specific treatment type
Progesterone type matters: Micronized progesterone and dydrogesterone show lower associated risk than synthetic progestins in observational studies
Experts recommend evaluating your baseline breast cancer risk before starting HRT and learning about modifiable risk factors that decrease risk regardless of hormone use.
Importantly, HRT-associated risks including breast cancer, stroke, and blood clots are rare; fewer than 10 events per 10,000 women, which is comparable to risks from other common medications.
Heart Disease and Timing
As emphasized earlier, cardiovascular effects depend critically on when you start. Early initiation (before 60 or within 10 years of menopause) reduces heart disease risk. Late initiation provides no benefit and may increase risk.
Blood Clots and Stroke
Blood clot risk remains rare (fewer than 10 events per 10,000 women) and can be further reduced by choosing transdermal forms (patches/gels) over pills, which bypass liver processing.
Similarly, transdermal preparations appear less likely to increase stroke risk compared to oral forms.
Autoimmune Disease
Recent research found modest associations between HRT and rheumatoid arthritis. Current users showed an 18% higher risk compared to non-users, with long-term use (4+ years) showing 19% higher risk. However, the absolute increase remains small. Women with autoimmune susceptibility should discuss individual risk-benefit ratios with their healthcare provider.
Who Should Consider HRT?
HRT may be appropriate for women who:
Have moderate to severe symptoms affecting quality of life
Are younger than 60 or within 10 years of menopause
Have no contraindications
Understand benefits and risks and prefer hormone treatment
Who Should Not Take HRT?
You should not use HRT if you have:
Estrogen-dependent cancers
History of blood clots, stroke, or cardiovascular disease
Active liver disease
Unexplained vaginal bleeding
Known or suspected pregnancy
Women with these conditions should explore alternatives with their healthcare provider.
Making Your Decision
As one major review emphasizes, decisions about menopause therapy should be personalized, considering your symptoms, health status, risk profile, life expectations, and treatment availability and cost.
Your decision should factor in:
How symptoms affect your quality of life
Your age and time since menopause
Personal and family medical history
Baseline cardiovascular and breast cancer risk
Your preferences and values
Healthcare providers and patients can use the extensive HRT research to make informed decisions about symptom management, disease prevention, and mortality reduction—keeping in mind that prevention strategies must be personalized.
Check Your Eligibility
Research demonstrates that HRT is a sex-specific, time-dependent therapy that reduces all-cause mortality and aging-related diseases when started appropriately, with an excellent risk profile for eligible women.
Women spend roughly 40% of their lives in menopause, and symptoms can substantially impair quality of life. You deserve to live those decades feeling your best, with effective symptom management and optimized long-term health.
The key is working with a knowledgeable healthcare provider who can assess your individual situation, discuss options thoroughly, and support you in making the choice that fits your health profile, symptom severity, and personal values.
If you’re experiencing menopause symptoms, consider connecting with a healthcare provider through Mochi Health to discuss whether hormone therapy might be right for you. Check your eligibility here
References:
Cobin RH, Goodman NF; AACE Reproductive Endocrinology Scientific Committee. AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY POSITION STATEMENT ON MENOPAUSE-2017 UPDATE. Endocrine Practice. 2017;23(7):869-880. doi:10.4158/EP171828.PS | PubMed
Davis SR, Lambrinoudaki I, Lumsden M, et al. Menopause. Nature Reviews Disease Primers. 2015;1:15004. doi:10.1038/nrdp.2015.4 | PubMed
Gava G, Orsili I, Alvisi S, et al. Cognition, Mood and Sleep in Menopausal Transition: The Role of Menopause Hormone Therapy. Medicina (Kaunas). 2019;55(10):668. doi:10.3390/medicina55100668 | PubMed
Gompel A, Simcock R. Menopausal hormone treatment and breast cancer. Lancet Diabetes & Endocrinology. 2026 Jan 28:S2213-8587(25)00394-8. doi:10.1016/S2213-8587(25)00394-8 | PubMed
Guimarães C, Balbinot E, Marçal F, et al. Hormone therapy in menopause increases rheumatoid arthritis risk: A systematic review and meta-analysis. Seminars in Arthritis and Rheumatism. 2026;77:152935. doi:10.1016/j.semarthrit.2026.152935 | PubMed
Hodis HN, Mack WJ. Menopausal Hormone Replacement Therapy and Reduction of All-Cause Mortality and Cardiovascular Disease: It Is About Time and Timing. Cancer Journal. 2022;28(3):208-223. doi:10.1097/PPO.0000000000000591 | PubMed
Soltani A, Voedisch AJ. A review of estrogens used in menopausal hormone therapy. Current Opinion in Obstetrics & Gynecology. 2026 Feb 2. doi:10.1097/GCO.0000000000001090 | PubMed
Stuenkel CA. Menopause, hormone therapy and diabetes. Climacteric. 2017;20(1):11-21. doi:10.1080/13697137.2016.1267723 | PubMed
Disclaimer: This article is for educational purposes only and should not be considered medical advice. The information provided does not constitute recommendations for treatment. Always consult with your healthcare provider about your specific situation, symptoms, and treatment options.
Share this post
Menopause
More articles
Read next
For iOS & Android
